Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma
Open Access
- 16 December 2024
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (4) , e183-e199.e8
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
- Cancer Prevention and Research Institute of Texas
This publication has 40 references indexed in Scilit:
- Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective studyCancer Medicine, 2023
- Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)Annals of Hematology, 2023
- RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphomaAnnals of Hematology, 2023
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trialThe Lancet, 2022
- Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy ExperienceClinical Lymphoma Myeloma and Leukemia, 2021
- Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphomaAmerican Journal of Hematology, 2021
- Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing AnalysisClinical Lymphoma Myeloma and Leukemia, 2021
- Real‐life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B‐cell lymphomasHematological Oncology, 2021
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 2020
- Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failureCancer, 2019